Cantor Fitzgerald Issues Negative Estimate for VNDA Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of Vanda Pharmaceuticals in a report issued on Thursday, May 8th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post earnings per share of ($1.55) for the year, down from their prior forecast of ($1.26). Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($1.12) per share.

Other analysts also recently issued research reports about the stock. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a "hold" rating for the company. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.

Vanda Pharmaceuticals Trading Up 2.7%

Vanda Pharmaceuticals stock traded up $0.11 during trading on Monday, hitting $4.04. The company had a trading volume of 165,104 shares, compared to its average volume of 723,067. Vanda Pharmaceuticals has a 1-year low of $3.81 and a 1-year high of $6.75. The company's 50 day simple moving average is $4.44 and its 200-day simple moving average is $4.63. The stock has a market cap of $237.80 million, a price-to-earnings ratio of -12.58 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The firm had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million.

Insider Transactions at Vanda Pharmaceuticals

In other news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the firm's stock in a transaction dated Friday, February 28th. The stock was acquired at an average cost of $4.76 per share, with a total value of $47,600.00. Following the transaction, the chief executive officer now owns 2,361,730 shares in the company, valued at approximately $11,241,834.80. This trade represents a 0.43% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders bought 32,000 shares of company stock valued at $151,180. Insiders own 10.00% of the company's stock.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of VNDA. Barclays PLC lifted its stake in shares of Vanda Pharmaceuticals by 128.2% during the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company's stock valued at $722,000 after buying an additional 86,677 shares during the period. JPMorgan Chase & Co. raised its stake in Vanda Pharmaceuticals by 16.1% during the third quarter. JPMorgan Chase & Co. now owns 160,722 shares of the biopharmaceutical company's stock worth $754,000 after purchasing an additional 22,249 shares during the period. SG Americas Securities LLC raised its stake in Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 5,459 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in Vanda Pharmaceuticals by 4.9% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company's stock worth $3,925,000 after purchasing an additional 38,449 shares during the period. Finally, Monaco Asset Management SAM raised its stake in Vanda Pharmaceuticals by 92.8% during the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company's stock worth $1,879,000 after purchasing an additional 188,836 shares during the period. Hedge funds and other institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.